Koers Genovis AB (publ.) Nasdaq Stockholm
Aandelen
SE0002485979
Medische apparatuur, benodigdheden & distributie
Omzet 2024 * | 155 mln. 14,07 mln. 13,19 mln. | Omzet 2025 * | 238 mln. 21,67 mln. 20,31 mln. | Marktkapitalisatie | 1,82 mld. 166 mln. 155 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 37 mln. 3,36 mln. 3,15 mln. | Nettowinst (verlies) 2025 * | 37 mln. 3,36 mln. 3,15 mln. | EV/omzet 2024 * | 11 x |
Nettoliquiditeiten 2024 * | 120 mln. 10,9 mln. 10,22 mln. | Nettoliquiditeiten 2025 * | 93 mln. 8,46 mln. 7,93 mln. | EV/omzet 2025 * | 7,26 x |
K/w-verhouding 2024 * |
48,5
x | K/w-verhouding 2025 * |
21,2
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 95,42% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Fredrik Olsson
CEO | Chief Executive Officer | 53 | 01-01-02 |
Magnus Långberg
DFI | Director of Finance/CFO | 53 | 01-01-22 |
Rolf Lood
CTO | Chief Tech/Sci/R&D Officer | 40 | 01-01-17 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 72 | 05-05-20 | |
Director/Board Member | 63 | 01-01-19 | |
Mikael Lönn
BRD | Director/Board Member | 75 | 01-01-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-0,60% | 12,63 mld. | |
-9,59% | 7,67 mld. | |
+1,82% | 5,42 mld. | |
+0,02% | 4,57 mld. | |
-47,68% | 3,51 mld. | |
+6,42% | 2,59 mld. | |
-14,59% | 2,05 mld. | |
-8,29% | 1,79 mld. | |
+2,25% | 1,77 mld. |